25 XP   0   0   10

Zydus Lifesciences Ltd
Buy, Hold or Sell?

Let's analyse Zydus Lifesciences Ltd together

PenkeI guess you are interested in Zydus Lifesciences Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Zydus Lifesciences Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Zydus Lifesciences Ltd

I send you an email if I find something interesting about Zydus Lifesciences Ltd.

Quick analysis of Zydus Lifesciences Ltd (30 sec.)










What can you expect buying and holding a share of Zydus Lifesciences Ltd? (30 sec.)

How much money do you get?

How much money do you get?
INR0.13
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
INR194.51
Expected worth in 1 year
INR228.07
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
INR44.12
Return On Investment
4.5%

For what price can you sell your share?

Current Price per Share
INR990.55
Expected price per share
INR685.85 - INR
How sure are you?
50%

1. Valuation of Zydus Lifesciences Ltd (5 min.)




Live pricePrice per Share (EOD)

INR990.55

Intrinsic Value Per Share

INR129.32 - INR150.38

Total Value Per Share

INR323.83 - INR344.89

2. Growth of Zydus Lifesciences Ltd (5 min.)




Is Zydus Lifesciences Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$2.3b$2.3b$76.7m3.2%

How much money is Zydus Lifesciences Ltd making?

Current yearPrevious yearGrowGrow %
Making money$237.1m$542.9m-$305.7m-128.9%
Net Profit Margin11.6%30.3%--

How much money comes from the company's main activities?

3. Financial Health of Zydus Lifesciences Ltd (5 min.)




What can you expect buying and holding a share of Zydus Lifesciences Ltd? (5 min.)

Welcome investor! Zydus Lifesciences Ltd's management wants to use your money to grow the business. In return you get a share of Zydus Lifesciences Ltd.

What can you expect buying and holding a share of Zydus Lifesciences Ltd?

First you should know what it really means to hold a share of Zydus Lifesciences Ltd. And how you can make/lose money.

Speculation

The Price per Share of Zydus Lifesciences Ltd is INR990.55. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Zydus Lifesciences Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Zydus Lifesciences Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR194.51. Based on the TTM, the Book Value Change Per Share is INR8.39 per quarter. Based on the YOY, the Book Value Change Per Share is INR40.29 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR2.64 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Zydus Lifesciences Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.230.0%0.230.0%0.530.1%0.290.0%0.290.0%
Usd Book Value Change Per Share0.100.0%0.100.0%0.490.0%0.590.1%0.590.1%
Usd Dividend Per Share0.030.0%0.030.0%0.040.0%0.040.0%0.040.0%
Usd Total Gains Per Share0.130.0%0.130.0%0.530.1%0.630.1%0.630.1%
Usd Price Per Share5.95-5.95-4.22-4.68-4.68-
Price to Earnings Ratio25.38-25.38-7.96-19.43-19.43-
Price-to-Total Gains Ratio44.56-44.56-7.94-17.18-17.18-
Price to Book Ratio2.53-2.53-1.87-2.44-2.44-
Price-to-Total Gains Ratio44.56-44.56-7.94-17.18-17.18-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share11.985655
Number of shares83
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.030.04
Usd Book Value Change Per Share0.100.59
Usd Total Gains Per Share0.130.63
Gains per Quarter (83 shares)11.0852.17
Gains per Year (83 shares)44.31208.69
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
111343413195199
221677827391408
33210112240586617
44213516653781826
553169210679771035
6642022548011721244
7742362989313671453
88527034210715631662
99530338612017581871
1010633743013319532080

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%4.00.00.0100.0%4.00.00.0100.0%4.00.00.0100.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%4.00.00.0100.0%4.00.00.0100.0%4.00.00.0100.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%4.00.00.0100.0%4.00.00.0100.0%4.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%4.00.00.0100.0%4.00.00.0100.0%4.00.00.0100.0%

Fundamentals of Zydus Lifesciences Ltd

About Zydus Lifesciences Ltd

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company offers the products under the Everyuth and Nutralite, Complan, Glucon D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India.

Fundamental data was last updated by Penke on 2024-03-02 05:08:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is fair priced.

1.1. Profitability of Zydus Lifesciences Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Zydus Lifesciences Ltd earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Zydus Lifesciences Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 11.6% means that ₹0.12 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Zydus Lifesciences Ltd:

  • The MRQ is 11.6%. The company is making a huge profit. +2
  • The TTM is 11.6%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ11.6%TTM11.6%0.0%
TTM11.6%YOY30.3%-18.6%
TTM11.6%5Y16.2%-4.6%
5Y16.2%10Y16.2%0.0%
1.1.2. Return on Assets

Shows how efficient Zydus Lifesciences Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Zydus Lifesciences Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 7.6% Return on Assets means that Zydus Lifesciences Ltd generated ₹0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Zydus Lifesciences Ltd:

  • The MRQ is 7.6%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 7.6%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ7.6%TTM7.6%0.0%
TTM7.6%YOY16.1%-8.5%
TTM7.6%5Y9.4%-1.8%
5Y9.4%10Y9.4%0.0%
1.1.3. Return on Equity

Shows how efficient Zydus Lifesciences Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Zydus Lifesciences Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 11.2% Return on Equity means Zydus Lifesciences Ltd generated ₹0.11 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Zydus Lifesciences Ltd:

  • The MRQ is 11.2%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 11.2%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ11.2%TTM11.2%0.0%
TTM11.2%YOY26.4%-15.2%
TTM11.2%5Y16.3%-5.1%
5Y16.3%10Y16.3%0.0%

1.2. Operating Efficiency of Zydus Lifesciences Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Zydus Lifesciences Ltd is operating .

  • Measures how much profit Zydus Lifesciences Ltd makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Zydus Lifesciences Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₹0.00  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Zydus Lifesciences Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY17.7%-17.7%
TTM-5Y12.9%-12.9%
5Y12.9%10Y12.9%0.0%
1.2.2. Operating Ratio

Measures how efficient Zydus Lifesciences Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.22 means that the operating costs are ₹1.22 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Zydus Lifesciences Ltd:

  • The MRQ is 1.219. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.219. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.219TTM1.2190.000
TTM1.219YOY1.225-0.006
TTM1.2195Y1.215+0.004
5Y1.21510Y1.2150.000

1.3. Liquidity of Zydus Lifesciences Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Zydus Lifesciences Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.81 means the company has ₹1.81 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Zydus Lifesciences Ltd:

  • The MRQ is 1.811. The company is able to pay all its short-term debts. +1
  • The TTM is 1.811. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.811TTM1.8110.000
TTM1.811YOY1.564+0.247
TTM1.8115Y1.384+0.427
5Y1.38410Y1.3840.000
1.3.2. Quick Ratio

Measures if Zydus Lifesciences Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Zydus Lifesciences Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.93 means the company can pay off ₹0.93 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Zydus Lifesciences Ltd:

  • The MRQ is 0.929. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.929. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.929TTM0.9290.000
TTM0.929YOY0.789+0.139
TTM0.9295Y0.669+0.259
5Y0.66910Y0.6690.000

1.4. Solvency of Zydus Lifesciences Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Zydus Lifesciences Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Zydus Lifesciences Ltd to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.24 means that Zydus Lifesciences Ltd assets are financed with 23.6% credit (debt) and the remaining percentage (100% - 23.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Zydus Lifesciences Ltd:

  • The MRQ is 0.236. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.236. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.236TTM0.2360.000
TTM0.236YOY0.314-0.079
TTM0.2365Y0.358-0.122
5Y0.35810Y0.3580.000
1.4.2. Debt to Equity Ratio

Measures if Zydus Lifesciences Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Zydus Lifesciences Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 34.6% means that company has ₹0.35 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Zydus Lifesciences Ltd:

  • The MRQ is 0.346. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.346. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.346TTM0.3460.000
TTM0.346YOY0.514-0.168
TTM0.3465Y0.676-0.330
5Y0.67610Y0.6760.000

2. Market Valuation of Zydus Lifesciences Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Zydus Lifesciences Ltd generates.

  • Above 15 is considered overpriced but always compare Zydus Lifesciences Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 25.38 means the investor is paying ₹25.38 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Zydus Lifesciences Ltd:

  • The EOD is 51.147. Based on the earnings, the company is expensive. -2
  • The MRQ is 25.379. Based on the earnings, the company is overpriced. -1
  • The TTM is 25.379. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD51.147MRQ25.379+25.769
MRQ25.379TTM25.3790.000
TTM25.379YOY7.955+17.423
TTM25.3795Y19.432+5.947
5Y19.43210Y19.4320.000
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Zydus Lifesciences Ltd:

  • The EOD is 60.476. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 30.008. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 30.008. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD60.476MRQ30.008+30.469
MRQ30.008TTM30.0080.000
TTM30.008YOY39.598-9.591
TTM30.0085Y26.297+3.711
5Y26.29710Y26.2970.000
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Zydus Lifesciences Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 2.53 means the investor is paying ₹2.53 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Zydus Lifesciences Ltd:

  • The EOD is 5.093. Based on the equity, the company is overpriced. -1
  • The MRQ is 2.527. Based on the equity, the company is underpriced. +1
  • The TTM is 2.527. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD5.093MRQ2.527+2.566
MRQ2.527TTM2.5270.000
TTM2.527YOY1.874+0.653
TTM2.5275Y2.440+0.087
5Y2.44010Y2.4400.000
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Zydus Lifesciences Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--8.3908.3900%40.286-79%48.627-83%48.627-83%
Book Value Per Share--194.509194.5090%186.119+5%160.212+21%160.212+21%
Current Ratio--1.8111.8110%1.564+16%1.384+31%1.384+31%
Debt To Asset Ratio--0.2360.2360%0.314-25%0.358-34%0.358-34%
Debt To Equity Ratio--0.3460.3460%0.514-33%0.676-49%0.676-49%
Dividend Per Share--2.6392.6390%3.636-27%3.322-21%3.322-21%
Eps--19.36719.3670%43.832-56%23.883-19%23.883-19%
Free Cash Flow Per Share--16.37916.3790%8.806+86%16.163+1%16.163+1%
Free Cash Flow To Equity Per Share--16.37916.3790%0.324+4951%5.149+218%5.149+218%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--150.376--------
Intrinsic Value_10Y_min--129.324--------
Intrinsic Value_1Y_max--16.099--------
Intrinsic Value_1Y_min--15.644--------
Intrinsic Value_3Y_max--47.586--------
Intrinsic Value_3Y_min--44.956--------
Intrinsic Value_5Y_max--78.127--------
Intrinsic Value_5Y_min--71.801--------
Market Cap1002634710000.000+50%497498334318.500497498334318.5000%356979044620.000+39%394808988152.125+26%394808988152.125+26%
Net Profit Margin--0.1160.1160%0.303-62%0.162-28%0.162-28%
Operating Margin----0%0.177-100%0.129-100%0.129-100%
Operating Ratio--1.2191.2190%1.2250%1.215+0%1.215+0%
Pb Ratio5.093+50%2.5272.5270%1.874+35%2.440+4%2.440+4%
Pe Ratio51.147+50%25.37925.3790%7.955+219%19.432+31%19.432+31%
Price Per Share990.550+50%491.500491.5000%348.700+41%387.038+27%387.038+27%
Price To Free Cash Flow Ratio60.476+50%30.00830.0080%39.598-24%26.297+14%26.297+14%
Price To Total Gains Ratio89.814+50%44.56544.5650%7.939+461%17.179+159%17.179+159%
Quick Ratio--0.9290.9290%0.789+18%0.669+39%0.669+39%
Return On Assets--0.0760.0760%0.161-53%0.094-19%0.094-19%
Return On Equity--0.1120.1120%0.264-58%0.163-31%0.163-31%
Total Gains Per Share--11.02911.0290%43.921-75%51.950-79%51.950-79%
Usd Book Value--2382284300.0002382284300.0000%2305509800.000+3%1977808525.000+20%1977808525.000+20%
Usd Book Value Change Per Share--0.1020.1020%0.487-79%0.588-83%0.588-83%
Usd Book Value Per Share--2.3542.3540%2.252+5%1.939+21%1.939+21%
Usd Dividend Per Share--0.0320.0320%0.044-27%0.040-21%0.040-21%
Usd Eps--0.2340.2340%0.530-56%0.289-19%0.289-19%
Usd Free Cash Flow--200605900.000200605900.0000%109081500.000+84%199640925.000+0%199640925.000+0%
Usd Free Cash Flow Per Share--0.1980.1980%0.107+86%0.196+1%0.196+1%
Usd Free Cash Flow To Equity Per Share--0.1980.1980%0.004+4951%0.062+218%0.062+218%
Usd Market Cap12131879991.000+50%6019729845.2546019729845.2540%4319446439.902+39%4777188756.641+26%4777188756.641+26%
Usd Price Per Share11.986+50%5.9475.9470%4.219+41%4.683+27%4.683+27%
Usd Profit--237196300.000237196300.0000%542963300.000-56%295173450.000-20%295173450.000-20%
Usd Revenue--2042213800.0002042213800.0000%1794139600.000+14%1825254750.000+12%1825254750.000+12%
Usd Total Gains Per Share--0.1330.1330%0.531-75%0.629-79%0.629-79%
 EOD+4 -4MRQTTM+0 -0YOY+19 -165Y+17 -1810Y+17 -18

3.2. Fundamental Score

Let's check the fundamental score of Zydus Lifesciences Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1551.147
Price to Book Ratio (EOD)Between0-15.093
Net Profit Margin (MRQ)Greater than00.116
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.929
Current Ratio (MRQ)Greater than11.811
Debt to Asset Ratio (MRQ)Less than10.236
Debt to Equity Ratio (MRQ)Less than10.346
Return on Equity (MRQ)Greater than0.150.112
Return on Assets (MRQ)Greater than0.050.076
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Zydus Lifesciences Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose989.650
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets257,564,000
Total Liabilities60,681,000
Total Stockholder Equity175,158,000
 As reported
Total Liabilities 60,681,000
Total Stockholder Equity+ 175,158,000
Total Assets = 257,564,000

Assets

Total Assets257,564,000
Total Current Assets100,164,000
Long-term Assets157,400,000
Total Current Assets
Cash And Cash Equivalents 4,878,000
Short-term Investments 7,188,000
Net Receivables 44,168,000
Inventory 34,133,000
Other Current Assets 186,000
Total Current Assets  (as reported)100,164,000
Total Current Assets  (calculated)90,553,000
+/- 9,611,000
Long-term Assets
Property Plant Equipment 68,267,000
Goodwill 48,044,000
Intangible Assets 10,905,000
Long-term Assets Other 181,000
Long-term Assets  (as reported)157,400,000
Long-term Assets  (calculated)127,397,000
+/- 30,003,000

Liabilities & Shareholders' Equity

Total Current Liabilities55,307,000
Long-term Liabilities5,374,000
Total Stockholder Equity175,158,000
Total Current Liabilities
Short Long Term Debt 11,632,000
Accounts payable 21,250,000
Other Current Liabilities 510,000
Total Current Liabilities  (as reported)55,307,000
Total Current Liabilities  (calculated)33,392,000
+/- 21,915,000
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt317,000
Long-term Liabilities  (as reported)5,374,000
Long-term Liabilities  (calculated)317,000
+/- 5,057,000
Total Stockholder Equity
Retained Earnings 171,898,000
Total Stockholder Equity (as reported)175,158,000
Total Stockholder Equity (calculated)171,898,000
+/- 3,260,000
Other
Capital Stock1,012,000
Common Stock Shares Outstanding 1,012,204
Net Debt 6,754,000
Net Invested Capital 186,790,000
Net Working Capital 44,857,000
Property Plant and Equipment Gross 113,293,000



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2023-03-312022-03-312021-03-312020-03-31
> Total Assets 
236,866,000
238,847,000
277,954,000
257,564,000
257,564,000277,954,000238,847,000236,866,000
   > Total Current Assets 
87,154,000
87,160,000
122,614,000
100,164,000
100,164,000122,614,00087,160,00087,154,000
       Cash And Cash Equivalents 
8,453,000
6,652,000
6,578,000
4,878,000
4,878,0006,578,0006,652,0008,453,000
       Short-term Investments 
4,943,000
4,620,000
28,470,000
7,188,000
7,188,00028,470,0004,620,0004,943,000
       Net Receivables 
36,632,000
31,273,000
33,403,000
44,168,000
44,168,00033,403,00031,273,00036,632,000
       Inventory 
27,890,000
32,362,000
37,194,000
34,133,000
34,133,00037,194,00032,362,00027,890,000
       Other Current Assets 
7,054,000
8,913,000
9,937,000
186,000
186,0009,937,0008,913,0007,054,000
   > Long-term Assets 
149,712,000
151,687,000
155,340,000
157,400,000
157,400,000155,340,000151,687,000149,712,000
       Property Plant Equipment 
61,937,000
63,332,000
64,226,000
68,267,000
68,267,00064,226,00063,332,00061,937,000
       Goodwill 
53,915,000
53,465,000
53,646,000
48,044,000
48,044,00053,646,00053,465,00053,915,000
       Intangible Assets 
13,868,000
12,363,000
11,272,000
10,905,000
10,905,00011,272,00012,363,00013,868,000
       Other Assets 
14,470,000
16,215,000
16,848,000
0
016,848,00016,215,00014,470,000
> Total Liabilities 
119,762,000
89,551,000
87,416,000
60,681,000
60,681,00087,416,00089,551,000119,762,000
   > Total Current Liabilities 
82,694,000
78,613,000
78,394,000
55,307,000
55,307,00078,394,00078,613,00082,694,000
       Short Long Term Debt 
47,718,000
39,740,000
38,339,000
11,632,000
11,632,00038,339,00039,740,00047,718,000
       Accounts payable 
20,310,000
22,059,000
21,378,000
21,250,000
21,250,00021,378,00022,059,00020,310,000
       Other Current Liabilities 
3,941,000
5,525,000
5,470,000
510,000
510,0005,470,0005,525,0003,941,000
   > Long-term Liabilities 
37,068,000
10,938,000
9,022,000
5,374,000
5,374,0009,022,00010,938,00037,068,000
       Long term Debt 
32,146,000
6,095,000
3,621,000
0
03,621,0006,095,00032,146,000
       Capital Lease Obligations Min Short Term Debt
274,000
241,000
249,000
317,000
317,000249,000241,000274,000
       Other Liabilities 
4,777,000
4,692,000
5,240,000
0
05,240,0004,692,0004,777,000
       Long-term Liabilities Other 
17,000
10,000
3,000
0
03,00010,00017,000
> Total Stockholder Equity
103,757,000
129,923,000
169,996,000
175,158,000
175,158,000169,996,000129,923,000103,757,000
   Common Stock
1,024,000
1,024,000
1,024,000
0
01,024,0001,024,0001,024,000
   Retained Earnings 
104,048,000
131,739,000
172,855,000
171,898,000
171,898,000172,855,000131,739,000104,048,000
   Capital Surplus 0000
   Treasury Stock0000
   Other Stockholders Equity 0-3,883,000-2,840,000-1,315,000



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue168,778,000
Cost of Revenue-65,589,000
Gross Profit103,189,000103,189,000
 
Operating Income (+$)
Gross Profit103,189,000
Operating Expense-140,229,000
Operating Income28,549,000-37,040,000
 
Operating Expense (+$)
Research Development1,358,000
Selling General Administrative21,401,000
Selling And Marketing Expenses0
Operating Expense140,229,00022,759,000
 
Net Interest Income (+$)
Interest Income757,000
Interest Expense-1,255,000
Other Finance Cost-43,000
Net Interest Income-541,000
 
Pretax Income (+$)
Operating Income28,549,000
Net Interest Income-541,000
Other Non-Operating Income Expenses0
Income Before Tax (EBT)25,897,00028,549,000
EBIT - interestExpense = -1,255,000
19,603,000
20,858,000
Interest Expense1,255,000
Earnings Before Interest and Taxes (EBIT)027,152,000
Earnings Before Interest and Taxes (EBITDA)34,423,000
 
After tax Income (+$)
Income Before Tax25,897,000
Tax Provision-5,878,000
Net Income From Continuing Ops20,965,00020,019,000
Net Income19,603,000
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0541,000
 

Technical Analysis of Zydus Lifesciences Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Zydus Lifesciences Ltd. The general trend of Zydus Lifesciences Ltd is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Zydus Lifesciences Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Zydus Lifesciences Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: .

The bearish price targets are: 920.55 > 696.65 > 685.85.

Tweet this
Zydus Lifesciences Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Zydus Lifesciences Ltd. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Zydus Lifesciences Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Zydus Lifesciences Ltd.

Zydus Lifesciences Ltd Daily Moving Average Convergence/Divergence (MACD) ChartZydus Lifesciences Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Zydus Lifesciences Ltd. The current adx is .

Zydus Lifesciences Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Zydus Lifesciences Ltd.

Zydus Lifesciences Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Zydus Lifesciences Ltd.

Zydus Lifesciences Ltd Daily Relative Strength Index (RSI) ChartZydus Lifesciences Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Zydus Lifesciences Ltd.

Zydus Lifesciences Ltd Daily Stochastic Oscillator ChartZydus Lifesciences Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Zydus Lifesciences Ltd.

Zydus Lifesciences Ltd Daily Commodity Channel Index (CCI) ChartZydus Lifesciences Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Zydus Lifesciences Ltd.

Zydus Lifesciences Ltd Daily Chande Momentum Oscillator (CMO) ChartZydus Lifesciences Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Zydus Lifesciences Ltd.

Zydus Lifesciences Ltd Daily Williams %R ChartZydus Lifesciences Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Zydus Lifesciences Ltd.

Zydus Lifesciences Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Zydus Lifesciences Ltd.

Zydus Lifesciences Ltd Daily Average True Range (ATR) ChartZydus Lifesciences Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Zydus Lifesciences Ltd.

Zydus Lifesciences Ltd Daily On-Balance Volume (OBV) ChartZydus Lifesciences Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Zydus Lifesciences Ltd.

Zydus Lifesciences Ltd Daily Money Flow Index (MFI) ChartZydus Lifesciences Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Zydus Lifesciences Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-10-26STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-10-27STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-10-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-02STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-09STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-10STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-22MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-23RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-19MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-01MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside

6.3. Candlestick Patterns

Zydus Lifesciences Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Zydus Lifesciences Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose989.650
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Zydus Lifesciences Ltd with someone you think should read this too:
  • Are you bullish or bearish on Zydus Lifesciences Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Zydus Lifesciences Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Zydus Lifesciences Ltd

I send you an email if I find something interesting about Zydus Lifesciences Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Zydus Lifesciences Ltd.

Receive notifications about Zydus Lifesciences Ltd in your mailbox!